Nova Mentis Organizes Autism Data Bank in North America
Vancouver, British Columbia – April 20, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it will be organizing a North American autism spectrum disorder (ASD) data bank to
Read More »
April 20, 2021
Nova Mentis Establishes Serotonin Research Centre
New Partnership with FourthWall Testing Vancouver, British Columbia – March 31, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it is establishing a serotonin research
Read More »
March 31, 2021
Nova Mentis Announces Promising Research Results
Psilocybin formulation Modulates Anxiety-Like Behaviour in Rat Autism Model Vancouver, British Columbia – March 29, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders, is pleased to announce, it has found early indications
Read More »
March 29, 2021
Nova Mentis Upgrades U.S. Listing to the OTCQB Venture Market
Vancouver, British Columbia – March 10, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company that is a global leader in the emerging field of serotonergic psychedelic medicine, is pleased to announce that it has been approved for trading on the OTCQB Venture Market effective today, March 10,
Read More »
March 10, 2021
Nova Mentis Launches Autism Microbiome Study in the United States
Vancouver, British Columbia – March 3, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a leader in the development of psilocybin and other entheogens, is pleased to announce the launch of its US-based Observational Study NM-101: “Microbiotic Diversity in Autism Spectrum Disorder (ASD): Improving Diagnostics by Differentiating Subtypes.”
Read More »
March 3, 2021
Nova Mentis Autism Clinical Study Approved by Institutional Review Board
Vancouver, British Columbia – February 25, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a leader in the development of psilocybin and other psychedelic compounds with broad cognitive, behavioral, and peripheral physiologic effects, has received approval for its first clinical program in Autism Spectrum Disorder (ASD). The Company has
Read More »
February 25, 2021